{"id":5,"date":"2016-09-23T09:41:42","date_gmt":"2016-09-23T13:41:42","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/ctwg\/clinical-trials-working-group\/"},"modified":"2020-05-13T13:29:49","modified_gmt":"2020-05-13T17:29:49","slug":"clinical-trials-working-group","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/ctwg\/","title":{"rendered":"Clinical Trials Working Group"},"content":{"rendered":"

The Clinical Trials Working Group provides a forum for faculty members and students to discuss current developments in statistical methods for clinical trials. It gives an opportunity to present preliminary work and to obtain feedback from the group.\u00a0The Working Group includes members of the Department of Biostatistics and statisticians in industry and academia. The atmosphere is informal and discussion is strongly encouraged.<\/p>\n

Contact<\/h3>\n

Interested speakers should contact Ludovic Trinquart<\/a>, Robert Lew<\/a>, or <\/span>Gheorghe Doros<\/a>.\u00a0 Feel free to reach out to be added to the Working Group mailing list.<\/span><\/p>\n

Schedule<\/h3>\n

2019-2020<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Date<\/span><\/td>\nSpeaker<\/span><\/td>\nTitle<\/span><\/td>\nLocation<\/span><\/td>\n<\/tr>\n
Nov 12th @5pm<\/td>\nRobert Lew<\/td>\nWho needs a control group?<\/td>\nCT-460A<\/td>\n<\/tr>\n
Dec 10th @5pm<\/td>\nYuyin Liu<\/td>\nNovel Statistical Methods for Multi-stage Designs in Clinical Trials with High Placebo Response<\/td>\nCT-460A<\/td>\n<\/tr>\n
Jan 23rd @5pm<\/td>\nDavid Cheng<\/td>\nAdaptive Combination of Conditional Treatment Effect Estimators Based on Randomized and Observational Data<\/td>\nCT-305<\/td>\n<\/tr>\n
Feb 27th @5pm<\/td>\nEdwin van den Heuven<\/td>\nStepped-wedge RCTs: optimal designs and challenges<\/td>\nCT-305<\/td>\n<\/tr>\n
March 17th, @5pm<\/td>\nAndrea Arf\u00e8<\/td>\nBayesian optimality of testing procedures for survival data in the non-proportional hazards setting<\/td>\nZoom<\/td>\n<\/tr>\n
April 28th, @5pm<\/td>\nAnne Eaton<\/td>\nNon-parametric estimation in an illness-death model with component-wise censoring<\/td>\nZoom<\/td>\n<\/tr>\n
May 12th, @5pm<\/td>\nAntara Majumdar<\/td>\nBayesian Synthetic Controls in Clinical Drug Development<\/td>\nZoom<\/td>\n<\/tr>\n
June 23rd, @5pm<\/td>\nMatthew Psioda<\/td>\nBayesian Sequential Monitoring of Clinical Trials<\/td>\nZoom<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

2017-2018<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Date<\/td>\nSpeaker<\/td>\nTitle<\/td>\nLocation<\/td>\nReadings<\/td>\n<\/tr>\n<\/thead>\n
Oct 6th\u00a0<\/sup>@4pm<\/td>\nPranab Ghosh<\/td>\nMulti-Arm Multi-Stage Design in Clinical Trials<\/td>\nCT-332<\/td>\nLink to reading<\/a><\/td>\n<\/tr>\n
Nov 3rd<\/sup>\u00a0@4pm<\/span><\/td>\nLudovic Trinquart<\/td>\nType S errors and exaggeration ratios in cancer randomized trials<\/td>\nCT-332<\/span><\/td>\n<\/td>\n<\/tr>\n
Nov 17th<\/sup>\u00a0@4pm<\/span><\/td>\nIsabelle Weir<\/td>\nDesign of noninferiority randomized trials using the difference in Restricted Mean Survival Times<\/td>\nCT-332<\/td>\n<\/td>\n<\/tr>\n
Dec 1st <\/sup>@4pm<\/td>\nIna Jazic (HSPH)<\/td>\nComposite endpoints in the semi-competing risks setting<\/td>\nCT-332<\/td>\nLink to reading<\/a><\/td>\n<\/tr>\n
Dec 15th<\/sup>\u00a0@4pm<\/span><\/td>\nSara Lodi<\/td>\nCausal inference methods for the per-protocol analysis of clinical trials<\/td>\nCT-332<\/td>\n<\/td>\n<\/tr>\n
Jan 19th<\/sup> @4pm<\/td>\nBrian Smith (Novartis)<\/td>\nImpact of the choice of endpoint and analysis on the ability to discern treatment effects: Why does the underlying statistical distribution used matter?<\/td>\nCT-332<\/td>\nLink to reading<\/a><\/td>\n<\/tr>\n
Feb 2nd<\/sup>\u00a0@4pm<\/td>\nRobert Lew<\/td>\nA Robust Method to Balance Factors over Time for Stepped Wedge\u00a0Cluster Randomized Trials<\/td>\nCT-332<\/td>\n<\/td>\n<\/tr>\n
Feb 16th<\/sup> @4pm<\/td>\nVivek Pradhan (Pfizer)<\/td>\nBias Reduction in Logistic Regression with Missing Responses when the Missing Data Mechanism is Nonignorable<\/td>\nCT-332<\/span><\/td>\n<\/td>\n<\/tr>\n
Mar 30th\u00a0@4pm<\/span><\/td>\nEleanor Murray (HSPH)<\/td>\nEstimating per-protocol effects in randomized trials: using the placebo arm to assess confounding<\/td>\nCT-332<\/span><\/td>\n<\/td>\n<\/tr>\n
TBD<\/td>\nEllie Gurary<\/td>\nType 1 Error Considerations in Superiority\/Non-Inferiority Seamless\u00a0Trial Design<\/td>\nCT-332<\/span><\/span><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

2016-2017<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Date<\/td>\nSpeaker<\/td>\nTitle<\/td>\nLocation<\/td>\nReadings<\/td>\n<\/tr>\n<\/thead>\n
October 12 @ 4:30pm<\/td>\nMark Chang<\/td>\nAdaptive Dose-finding clinical trials<\/td>\nCT-332<\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
October 28 @ 4:30pm<\/td>\nLudovic Trinquart<\/td>\nMeta-analysis of survival data from randomized trials using restricted mean survival times<\/td>\nCT-332<\/td>\nLink to reading #1<\/a><\/td>\n<\/tr>\n
November 9 @4:30pm<\/td>\nMizue Krygowski<\/td>\nPersonalized medicine integrated in Clinical Trial design<\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
November 18 @4:30pm<\/td>\nMeg Short<\/td>\nPK variability in Phase I oncology trials<\/span><\/td>\nCT-332<\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
December 7 @4:30pm<\/td>\nMike LaValley<\/td>\nPublication Bias in Meta-Analysis<\/td>\nCT-332<\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
December 16 @ 4:30pm<\/td>\nDenis Rybin<\/td>\nTreatment of dropout in clinical trials: A case study<\/td>\nCT-332<\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
January 11 @ 4:30pm<\/td>\nOkwuokenye Macaulay<\/span><\/td>\nDiscrete Time-to-event and Score-based Methods with Application to Composite Endpoint for Assessing Evidence of Disease Activity-Free<\/span><\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
January 27 @ 4:30pm<\/td>\nRobert Lew<\/td>\nRobust Priors for Small Samples<\/td>\nCT-332<\/td>\nLink to reading #1<\/a><\/td>\n<\/tr>\n
February 8 @ 4:30 pm<\/td>\nJeremiah Perez<\/td>\nA comparison of risk measures in safety outcome trials designed to rule out excess risk<\/span><\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
February 24, 2017 @4:30<\/td>\nRobert Lew<\/span><\/td>\nSecondary Analyses for Clustered Trials<\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
March 17 @4:30<\/span><\/td>\nSandeep Menon<\/span><\/td>\nOverview of personalized medicine designs<\/span><\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/span><\/td>\n<\/tr>\n
March 27\u00a0@4:30 pm<\/td>\nBo Yang<\/td>\nOptimal group sequential design with flexible timing of sample size determination<\/p>\n

<\/span><\/td>\n

CT-332<\/span><\/td>\nLink to reading #1<\/span><\/span><\/td>\n<\/tr>\n
April 7 @4:30 pm<\/td>\nZhaoyang Teng<\/span><\/td>\nOptimal Sample Size Planning for Phase II Trials<\/span><\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n
April 26 @4:30 pm<\/span><\/td>\nVivek Pradhan<\/td>\nAppropriate binomial confidence interval to be used in practice
\n<\/span><\/td>\n		CT-332<\/span><\/span><\/td>\nLink to reading #1<\/span><\/td>\n<\/tr>\n
May 17 @4:30 pm<\/span><\/td>\nSarah C. Conner<\/td>\nAdjusted restricted mean survival times in observational studies<\/span><\/td>\nCT-332<\/span><\/td>\nLink to reading #1<\/span><\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

The Clinical Trials Working Group provides a forum for faculty members and students to discuss current developments in statistical methods for clinical trials. It gives an opportunity to present preliminary work and to obtain feedback from the group.\u00a0The Working Group includes members of the Department of Biostatistics and statisticians in industry and academia. The atmosphere […]<\/p>\n","protected":false},"author":10952,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/pages\/5"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/users\/10952"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/comments?post=5"}],"version-history":[{"count":51,"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/pages\/5\/revisions"}],"predecessor-version":[{"id":101,"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/pages\/5\/revisions\/101"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/ctwg\/wp-json\/wp\/v2\/media?parent=5"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}